Clinical Research Leads to New Treatments
The doctors at Retina Consultants of Orange County are committed to bringing the most advanced medical and surgical care available. As part of this commitment, we are improving upon current treatments through research. Research studies include only people who choose to take part, and only those patients who qualify. Each trial has different requirements for enrollment. Patients are encouraged to take their time in making a decision about participating; and can discuss the decision with their family or friends. Any study related questions can be answered by the doctors or clinical research coordinator.
Trial Phases
Clinical research trials are conducted in a series of phases; each one is designed to answer a separate research question about the investigated drug.
Phase 1: Researchers test a new treatment in a small group of people for the first time to evaluate its safety and determine a safe dosage range; side effects are identified.
Phase 2: The treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The treatment is given to large groups of people to confirm effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug’s effect in various populations and any side effects associated with long-term use.
Active Clinical Research Trials
We are involved in many active research trials for retina diseases. Ask your Retina Consultants of Orange County physician if you have a condition that may lead you to qualify for one of the trials.
Iveric Bio, Protocol ISEE2008 (Dry Macular Degeneration, Geographic Atrophy) Phase III
Apellis, “Oaks” Protocol APL2-304 (Dry Macular Degeneration, Geographic Atrophy) Phase III
Roche, “GAllego” Protocol GR40973 (Dry Macular Degeneration, Geographic Atrophy) Phase II
NGM Bio, "Catalina" Protocol NGM-621 (Dry Macular Degeneration, Geographic Atrophy) Phase II
Gemini, “GE-NH-001" (Dry Macular Degeneration, Geographic Atrophy) DNA Study
Kodiak, “Dazzle” Protocol KSI-CL-102 (Wet Macular Degeneration) Phase II
Chengdu, “Panda” Protocol KHB-1801 (Wet Macular Degeneration) Phase III
Regeneron, "Candela" HD-AMD-1905 (Wet Macular Degeneration) Phase II
Regeneron, "Pulsar" Protocol 20968 (Wet Macular Degeneration) Phase III
Parexel, "Amgen" Protocol 20170542 (Wet Macular Degeneration) Phase III
Roche, “Rhine” Protocol GR40398 (Diabetic Macular Edema) Phase III
Roche, "Rhone-X" Protocol GR41987 (Diabetic Macular Edema) Phase IV
Regeneron, “Photon" Protocol HD-DME-1934 (Diabetic Macular Edema) Phase II/III
Roche, "Pagoda" Protocol GR40550, Port Delivery (Diabetic Macular Edema) Phase III
Roche, "Pavilion" Protocol GR41675, Port Delivery (Non-Proliferative Diabetic Retinopathy) Phase III
